Highest-materiality recent filing
Corbus reports CRB-701 42.9% cORR in 2L OPSCC at 3.6 mg/kg; registrational study planned summer 2026
cORR 42.9% (9/21) in 2L OPSCC at 3.6 mg/kg; median DOR 6.3 mo, PFS 5.6 mo.
Corbus appoints Nishant Saxena as first Chief Business Officer; schedules CRB-701 data call
Nishant Saxena appointed CBO; base salary $470K, 192,300 options and 58,300 RSUs as initial equity.
Corbus Q1 net loss $23M, cash $138.2M; FDA alignment for CRB-701 registration path
Net loss of $23.0M ($1.23 diluted LPS) vs $17.0M loss ($1.39 LPS) in Q1 2025.
Last patient enrolled and completed first visit in CANYON-1 Phase 1b trial of CRB-913, a peripherally restricted oral CB1 inverse agonist.
Corbus Pharma announces FDA alignment for CRB-701 accelerated path; CMO resigns
FDA agreed on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, with potential accelerated approval using ORR primary endpoint.
Corbus Q4 net loss $20.6M; cash $163.3M into 2028; key CRB-701/913 catalysts mid-2026
Q4 2025 net loss $20.6M ($1.25/share) vs $9.5M ($0.78) in Q4 2024; operating expenses rose to $22.0M.
Corbus posts Phase 1a data for CRB-913: weight loss signal, no serious AEs; Phase 1b started
Phase 1a SAD/MAD of oral CB1 inverse agonist CRB-913 (n=112) showed no serious AEs, no GI intolerability, no neuropsychiatric events except mild anxiety/irritability in obese cohort.
Corbus Q3 net loss $23.3M ($1.90/sh); cash $104M; CRB-701 ORR 47.6% in HNSCC
Net loss of $23.3M ($1.90 diluted EPS) vs $13.8M ($1.15) in Q3 2024; operating expenses up $8.9M.
Corbus Pharmaceuticals prices $75M public offering of common stock and warrants
Offering of 4,744,231 shares at $13.00/share and 1,025,000 pre-funded warrants at $12.9999 each for ~$75M gross proceeds.
Corbus Pharma reports CRB-701 Phase 1/2 ORR 47.6% HNSCC, 55.6% mUC at ESMO25
3.6 mg/kg dose: ORR 47.6% in HNSCC (n=21), 37.5% in cervical cancer (n=16), 55.6% in mUC (n=9).
Corbus Pharmaceuticals Q2 2025 Net Loss $17.7M, Pipeline on Track for Data Readouts H2 2025
Net loss for Q2 2025 was $17.7 million ($1.44 per share), compared to $10.0 million loss in Q2 2024.
Corbus Pharma Q1 net loss $17M; pipeline on track for data in H2 2025
Net loss of $17.0M ($1.39/share) vs $6.9M ($0.83) in Q1 2024; operating expenses rose to $19.8M.
Corbus reports Q4 net loss $9.5M, cash $149.1M; pipeline updates on CRB-701, CRB-913, CRB-601
Net loss Q4 2024 $9.5M ($0.78/share) vs $8.0M ($1.81/share) in Q4 2023; full-year loss $40.2M ($3.68/share).
Corbus CRB-701 Phase 1 Western data: low neuropathy, HNSCC responses, dose optimization started
No DLTs; peripheral neuropathy 5% (Grade 1-2) vs 3% in China; combined 4% across 75 patients.
FDA grants Fast Track designation to Corbus' CRB-701 for cervical cancer
CRB-701 is a next-generation Nectin-4 ADC with site-specific cleavable linker, MMAE payload, DAR 2.
Corbus Q3 net loss $13.8M; CRB-701 dose escalation complete; cash $159.4M
Net loss of $13.8M ($1.15/diluted share) vs $10.1M ($2.27) in Q3 2023; operating expenses up $6.0M to $15.5M.
Corbus presents pre-clinical data for obesity drug CRB-913; Phase 1 start Q1 2025
CRB-913 showed 15-fold lower brain levels vs monlunabant in mice; plasma-to-brain ratio 10x better than monlunabant.
Corbus Pharma Q2 loss $10M; CRB-701 shows 44% ORR in mUC; cash runway through Q3 2027
Net loss of $10.0M ($0.90 per diluted share) for Q2 2024, compared to net loss of $8.8M ($2.05 per share) in Q2 2023.
Corbus reports Phase 1 data for CRB-701 at ASCO: 44% ORR in mUC, 43% in cervical cancer
44% ORR and 78% DCR in mUC (n=9), 43% ORR and 86% DCR in cervical cancer (n=7) at doses ≥1.2 mg/Kg.
Corbus Q1 net loss narrows to $6.9M; raised $116M, cash runway through Q1 2027
Net loss of $6.9M ($0.83/diluted share) vs $17.7M ($4.24) in Q1 2023, driven by lower operating expenses.
Corbus Pharma reports Q4 net loss $8.0M; cash $127M after $116M raise; CRB-701 shows 43% ORR
Net loss Q4 $8.0M ($1.81/diluted) vs $10.9M ($2.61) YoY; full year loss $44.6M ($10.31).
Corbus Pharmaceuticals prices public offering of 4.325M shares at $19, expects ~$88.5M net proceeds
Priced 4,325,000 shares of common stock at $19.00 per share; underwriters' option for additional 648,750 shares exercised in full.
Phase 1 dose-escalation data for CRB-701 (SYS6002) in nectin-4 positive tumors presented at ASCO GU 2024.
Corbus receives FDA IND clearance for CRB-601; Nasdaq grants extension to May 8, 2024
FDA cleared IND for CRB-601, a TGFβ blocking monoclonal antibody targeting integrin αvβ8.
Corbus receives Nasdaq delisting notice for equity below $2.5M minimum
Nasdaq notified Corbus on Nov 10, 2023 that stockholders' equity of $311,016 as of Sept 30, 2023 is below the $2.5M minimum for continued listing.
On May 19, 2026, the Compensation Committee granted Brent Pfeiffenberger the following initial equity awards under the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) in connection with his appointment to the Board
On May 13, 2026, the board of directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Brent Pfeiffenberger, age 48, to serve as a member of the Board, thereby expanding the Board to seven members.
Dr. Peter Salzmann advised the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”) that he will not stand for re-election as a director of the Company at the 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
On March 13, 2025, the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”) appointed Ian Hodgson as Chief Operating Officer effective March 15, 2025.
Effective August 16, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Winston W. Kung, age 49, to serve as a member of the Board.
On August 15, 2024, Avery W. Catlin submitted his resignation from the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), effective as of August 15, 2024.
On February 2, 2024, Rachael Brake, Ph.D., Chief Scientific Officer of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), submitted a notice of resignation to the Company.
On April 24, 2023, Mr. Millian and the Company entered into a Separation and General Release Agreement (the “Separation Agreement”) related to Mr. Millian’s resignation as Chief Operating Officer from the Company.
On March 3, 2023, Craig Millian, Chief Operating Officer of the Company, submitted a notice of resignation to the Company to pursue other opportunities.
On March 1, 2023, the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Yong Ben, M.D., MBA, age 49, to serve as a member of the Board.
appointed Anne Altmeyer, Ph.D., MBA, MPH, age 58, to serve as a member of the Board.
Max materiality 0.85 · Median 0.57 · Most common event other_material